Arcutis Biotherapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for immune-mediated dermatological diseases. Headquartered in California, the company specializes in non-steroidal topical therapies for chronic skin conditions such as plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. Its lead commercial product is ZORYVE (roflumilast), which is available in both cream and foam formulations and addresses significant unmet needs in medical dermatology. Arcutis operates primarily in the United States, leveraging its dermatology development platform to build differentiated therapies against biologically validated targets. The company's pipeline also includes additional topical and oral therapeutic candidates in various stages of clinical development for inflammatory skin conditions.
